Nadav Kidron Net Worth

The estimated Net Worth of Nadav Kidron is at least $6.28 Million dollars as of 16 March 2023. Mr. Kidron owns over 26,000 units of Oramed Pharmaceuticals, Inc stock worth over $299,880 and over the last 17 years he sold ORMP stock worth over $4,424,200. In addition, he makes $1,551,100 as President, Chief Executive Officer, and Director at Oramed Pharmaceuticals, Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Kidron ORMP stock SEC Form 4 insiders trading

Nadav has made over 9 trades of the Oramed Pharmaceuticals, Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 26,000 units of ORMP stock worth $53,040 on 16 March 2023.

The largest trade he's ever made was selling 220,000 units of Oramed Pharmaceuticals, Inc stock on 9 August 2021 worth over $4,424,200. On average, Nadav trades about 11,404 units every 94 days since 2007. As of 16 March 2023 he still owns at least 126,000 units of Oramed Pharmaceuticals, Inc stock.

You can see the complete history of Mr. Kidron stock trades at the bottom of the page.

Nadav Kidron biography

Nadav Kidron serves as President, Chief Executive Officer, Director of the Company. He is also a director of Israel Advanced Technology Industries organization, and until 2016 was a director of Entera Bio Ltd. In 2009, he was a fellow at the Merage Foundation for U.S.-Israel Trade Programs for executives in the life sciences field. From 2003 to 2006, he was the managing director of the Institute of Advanced Jewish Studies at Bar Ilan University. From 2001 to 2003, he was a legal intern at Wine, Mishaiker & Ernstoff Law Offices in Jerusalem, Israel. Mr. Kidron holds an LL.B. and an International MBA from Bar Ilan University, Israel, and is a member of the Israel Bar Association.

What is the salary of Nadav Kidron?

As the President, Chief Executive Officer, and Director of Oramed Pharmaceuticals, Inc, the total compensation of Nadav Kidron at Oramed Pharmaceuticals, Inc is $1,551,100. There are no executives at Oramed Pharmaceuticals, Inc getting paid more.

How old is Nadav Kidron?

Nadav Kidron is 46, he's been the President, Chief Executive Officer, and Director of Oramed Pharmaceuticals, Inc since 2006. There are 12 older and 2 younger executives at Oramed Pharmaceuticals, Inc. The oldest executive at Oramed Pharmaceuticals, Inc is Dr. Miriam Kidron Ph.D., 81, who is the Chief Scientific Officer & Director.

Insiders trading at Oramed Pharmaceuticals, Inc

Over the last 17 years, insiders at Oramed Pharmaceuticals, Inc have traded over $7,377,390 worth of Oramed Pharmaceuticals, Inc stock and bought 881,642 units worth $3,583,418 . The most active insiders traders include Miriam Kidron, Leonard Sank, and Nadav Kidron. On average, Oramed Pharmaceuticals, Inc executives and independent directors trade stock every 111 days with the average trade being worth of $97,149. The most recent stock trade was executed by Arie Mayer on 3 April 2023, trading 8,809 units of ORMP stock currently worth $19,556.

What does Oramed Pharmaceuticals, Inc do?

oramed pharmaceuticals (nasdaqcm:ormp) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection. through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 trials under the usfda, the company is seeking to revolutionize the treatment of diabetes. read more: http://www.oramed.com/investors/corporate-presentation watch: https://www.youtube.com/watch?v=5qchxtdv9eg

Complete history of Mr. Kidron stock trades at Oramed Pharmaceuticals, Inc

Oramed Pharmaceuticals, Inc executives and stock owners

Oramed Pharmaceuticals, Inc executives and other stock owners filed with the SEC include:

• Nadav Kidron,
  President, Chief Executive Officer, Director
• Nadav Kidron Esq.,
  Pres, CEO & Exec. Director
• Miriam Kidron,
  Chief Scientific Officer, Director
• Joshua Hexter,
  Chief Operating and Business Officer
• Dr. Miriam Kidron Ph.D.,
  Chief Scientific Officer & Director
• Dr. Miriam Kidron,
  Chief Scientific Officer & Director
• Michael Rabinowitz,
  Chief Commercial Officer
• Joshua Hexter,
  Chief Operating & Bus. Officer
• David Silberman,
  CFO, Treasurer & Sec.
• Avraham Gabay,
  Chief Financial Officer, Treasurer, Secretary
• Kevin Rakin,
  Independent Chairman of the Board
• Leonard Sank,
  Independent Director
• Arie Mayer,
  Independent Director
• Xiaoming Gao,
  Independent Director
• Aviad Friedman,
  Independent Director
• Dr. Roy Eldor M.D., Ph.D.,
  Chief Medical Advisor & Member of the Scientific Advisory Board
• Daniel Aghion,
  Director
• Capital Management Lp Regal...,
  
• Xiaopeng Li,
  Director
• David Mark Slager,
  Director
• Harold Jacob,
  Director
• Gerald M Ostrov,
  Director
• Capital Management Lp Regals,
  10% owner
• Ronald Edward Law,
  Chief Strategy Officer
• Michael Berelowitz,
  Director
• Yifat Hen Zommer,
  CFO, Treasurer and Secretary
• Hilla Eisenberg,
  CFO, Treasurer and Secretary
• David Silberman,
  Chief Financial Officer
• Mark Daniel Hasleton,
  VP Business Development
• Michael Rabinowitz,
  Chief Commercial Officer
• Chaime Orlev,
  CFO, TREASURER AND SECRETARY
• Benjamin Shapiro,
  Director
• Michael Rabinowitz,
  Chief Commercial Officer
• Netanel Derovan,
  Chief Legal Officer
• Yadin Rozov,
  Director
• Yehuda Reznick,
  Director